OKYO Pharma Ltd.
OKYO Pharma Ltd.
07/23/2026 | Press release | Distributed by Public on 07/23/2026 10:00
OKYO Pharma Announces Purchase of Shares by Director
OKYO Pharma Announces Purchase of Shares by Director
Jul 23, 2026
London and New York, NY, July 23, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma's Non-Executive Director, John Brancaccio has purchased 5,000 of the Company's ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares.
About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
For further information, please visit https://www.okyopharma.com.
For further inquiries:
OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: [email protected]
OKYO Pharma Ltd. published this content on July 23, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 23, 2026 at 16:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]